EGFR and neoplasm: Several studies have investigated potential tissue-based biomarkers for predicting progression-free survival (PFS) in mCRC, including tumor DNA mutations (Bhattacharya, 2023; Ohnmacht et al, 2023), Consensus molecular subtypes (CMS) (Stahler et al, 2023), and molecular alterations linked to the EGFR pathway (Battaglin et al, 2024; Bhattacharya, 2023).